Menu
ncarol.com
  • Home
  • Education
  • Health
  • Books
  • Technology
  • Business
  • Entertainment
  • Financial
  • Real Estate
ncarol.com

Precision BioSciences to Participate in Upcoming H.C. Wainwright Cell Therapy Virtual Conference
ncarol.com/10212254

Trending...
  • UK Financial Ltd Launches UKFL Premier One as Its Official Broadcast Channel for Premium Content, Podcasts & Independent Expert Analysis
  • Dual-Engine Growth Strategy Unleashed Targeting a $9.1B Market and the Exploding AI Biotech Revolution: KALA BIO (N A S D A Q: KALA)
  • GitKraken Desktop 12.0 Introduces Agent Mode: Gives Developers Ultimate Control & Visualization While Scaling Parallel Agent Workflows
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C. Wainwright Cell Therapy Virtual Conference taking place February 28, 2023.

Details for the virtual fireside chat are as follows:
Date: Tuesday, February 28, 2023
Time: 2:00 PM ET

The fireside chat will be available via a live webcast accessible on Precision's website in the Investors section under Events & Presentations on February 28, 2023: https://investor.precisionbiosciences.com/events-and-presentations. An archived replay will be available for approximately 30 days following the event.

More on ncarol.com
  • L2 Aviation Acquires Advance Aero
  • $112 Million Contract Backlog for Cycurion (N A S D A Q: CYCU) Enters Hyper-Growth Phase With, Strategic Acquisitions, & Exploding AI Cybersecurity
  • HarryPotterObamaSonic10Inu Celebrates World Record 1,000+ Days Livestream with Record-Breaking Merchandise Launch
  • Igniting High-Growth Expansion as Electrification Strategy and Infrastructure Dominance Converge; 88% Revenue Growth (N Y S E: MWG)
  • Appliance EMT Presents Multi-Thousand Dollar Donation to Kids Motel Ministry to Support Local Families

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple ex vivo "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

Contacts

Investor Contact:

Mei Burris
Director, Investor Relations & Finance
Mei.burris@precisionbiosciences.com

Media Contact:
Maurissa Messier
Senior Director, Corporate Communications
Maurissa.Messier@precisionbiosciences.com
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Finding the Best Lawyer: What Really Matters When Your Case Is on the Line
  • The New World of Freight Brokering with AI
  • Captain Notepad Launches Full-Service Direct Mail Platform for Small Businesses Nationwide
  • World Cup Buzz Fuels Nayarit's Rise as Mexico's Pacific Standout
  • Nayarit strengthens its position in Mexico's Culinary Elite with 8 restaurants in the 2026 Mexico Gastronomic Guide
  • Winter Garden Ski Lake Home Sells for $2.05M in Cash Transaction, Highlighting Demand for Strategically Positioned Luxury Properties
  • Strobert Tree Services' "50 Shades of Green" Campaign Encourages Arbor Day Action Across Delaware and Pennsylvania
  • As Fluoride Debate Grips the Nation, Americans Turn to Whole-House Fluoride Filters for Answers
  • FOCUS Hires Carrier-Side Operations Leader to Build the Next Generation of Insurance Service Delivery
  • Adams Security Group LLC Launches New Website to Expand Professional Security Services Across Florida
  • Presidential Acceleration of Psychedelic Therapies Enters a Defining Moment as Federal Policy, FDA Alignment & Breakthrough Neurotechnology Converge
  • Peernovation And Inception Stratos Launch Joint Venture To Build A Global Peer-powered Performance Platform
  • GDE Tree Services Expands Operations Across Logan, Ipswich and the Gold Coast
  • UK AltNet FullFibre Solves IPv4 Shortage With netElastic BNG And CGNAT Networking Software
  • Studica Robotics Receives 2026 Partner Excellence Award from FIRST® Robotics Canada
  • Seven Games That Make You Think (and Smile) Earn 2026 Mensa Select® Honors
  • New Research Reveals Gen Z Trusts Independent Sources Over Influencers — Exposing What We are Talker Calls "The Independent Validation Gap"
  • New research identifies The Discovery Gap: Seven in 10 Americans say travel is no longer just about getting away
  • PropAccount.com Adds Equities to Its Multi-Asset Prop Firm Platform, Opening the Door to the World's Largest Trading Market
  • Ailias Launches Global Partner Programme for AI-Powered Conversational Digital Humans in Events and Experiences
_catLbl0 _catLbl1

Popular on ncarol.com

  • Registered Nurse Launches Healthcare Wealth Strategy Practice for Healthcare Professionals - 382
  • Homeowner Prep Announces Strategic Language Shift: Replacing "Renters" with "Future Homeowners" to Inspire Wealth-Building Mindsets - 149
  • Larry R. Wasion Highlights Jump Gate I: Time Chair. The Opening Novel in His Expansive Science Fiction Series
  • UK Financial Ltd Launches UKFL Premier One as Its Official Broadcast Channel for Premium Content, Podcasts & Independent Expert Analysis
  • LiposoMore™ Redefines Bioavailability: Joyful Nutritional Launches High-Performance Liposomal Vitamin C and Iron for the Global Supplement Market
  • Sycor Introduces Spring Release 2026 of Sycor.Rental with AI-Driven Innovations and Enhanced Service Processes
  • Rhealize Strategic Talent Advisory Co-Founder Dona Baker to Speak at DisruptHR YEG 15.0 in Edmonton on Hiring Innovation
  • Pacific Emblem Company Launches "Happy 250th Birthday America" Collection and Proud Supporter of the Gary Sinise Foundation
  • UK Financial Ltd Tokenized LTNS 1, A $1.1 T Asset-Backed ERC-3643 Security Token with 11 On-Chain Contracts Verifying, Compliant Real-World Value
  • Dual-Engine Growth Strategy Unleashed Targeting a $9.1B Market and the Exploding AI Biotech Revolution: KALA BIO (N A S D A Q: KALA)

Similar on ncarol.com

  • Apple Rock Open House Offers Behind-the-Scenes Look at Exhibit Production
  • $112 Million Contract Backlog for Cycurion (N A S D A Q: CYCU) Enters Hyper-Growth Phase With, Strategic Acquisitions, & Exploding AI Cybersecurity
  • HarryPotterObamaSonic10Inu Celebrates World Record 1,000+ Days Livestream with Record-Breaking Merchandise Launch
  • Igniting High-Growth Expansion as Electrification Strategy and Infrastructure Dominance Converge; 88% Revenue Growth (N Y S E: MWG)
  • Appliance EMT Presents Multi-Thousand Dollar Donation to Kids Motel Ministry to Support Local Families
  • 50 Years of Small Business Wisdom, Supercharged by AI: Shelly Berman Launches The Business Health Check
  • Deborah E. Jones Releases Emotional Sovereignty, a Book on Emotional Awareness and Self-Regulation
  • The New World of Freight Brokering with AI
  • As Fluoride Debate Grips the Nation, Americans Turn to Whole-House Fluoride Filters for Answers
  • Presidential Acceleration of Psychedelic Therapies Enters a Defining Moment as Federal Policy, FDA Alignment & Breakthrough Neurotechnology Converge
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute